Anyone researching psychedelic-assisted approaches to PTSD eventually arrives at the same question: ayahuasca or MDMA-assisted therapy? The two are frequently discussed in the same sentence, but they are mechanistically distinct, sit at very different regulatory stages, and are supported by different kinds of evidence. This page lays out what each evidence base actually shows, without declaring a winner — because the honest answer depends on the individual case, not on which substance has better marketing.

MDMA: An Entactogen, Not a Classical Psychedelic

MDMA (3,4-methylenedioxymethamphetamine) is technically an entactogen — it produces a state of emotional openness, reduced fear response, and increased interpersonal trust without the perceptual distortion typical of classic psychedelics. Mechanistically it triggers a large release of serotonin along with dopamine and norepinephrine, and it appears to reduce amygdala reactivity while maintaining prefrontal engagement, a combination researchers have proposed creates a window in which traumatic material can be discussed without triggering the full fear response.

A randomized, double-blind, placebo-controlled phase 3 study found that MDMA-assisted therapy produced significant reductions in PTSD symptom severity compared with placebo plus the same therapy (Mitchell et al., 2021). A longitudinal pooled analysis of long-term follow-up outcomes from earlier phase 2 trials reported that symptom improvements were largely maintained at extended follow-up (Jerome et al., 2020). It is important to state plainly: despite this trial evidence, MDMA-assisted therapy for PTSD is not an approved treatment. It has Breakthrough Therapy Designation from the FDA, which expedites review, but it is not available as a prescription therapy and is not something Sanctuary Tulum offers.

Ayahuasca: A Classical Serotonergic Psychedelic With DMT and an MAOI

Ayahuasca is a brew combining DMT-containing plants with MAOI-containing plants, typically Banisteriopsis caapi. The MAOI component allows orally ingested DMT to become active by preventing its rapid breakdown in the gut. The resulting experience is longer, more perceptually vivid, and less socially interactive than an MDMA session. Pharmacokinetic work in healthy volunteers has characterized how the alkaloids in the brew are absorbed and metabolized (Callaway et al., 1999), and broader reviews describe ayahuasca's psychological and physiological effects and its potential relevance to addiction and mental illness more generally (Hamill et al., 2019).

The PTSD-specific evidence base for ayahuasca is smaller and more observational than the MDMA trial data. Its depression evidence is more developed (Palhano-Fontes et al., 2022), and separate work on affect and cognitive thinking style following ceremony suggests durable shifts beyond the acute experience (Uthaug et al., 2018) — but this is not the same as a placebo-controlled PTSD trial. Readers should not treat ayahuasca's broader psychiatric literature as equivalent to direct PTSD trial evidence; it is adjacent, not identical.

Ayahuasca retreat medically supervised in Tulum — where plant-medicine and clinical PTSD care intersect at Sanctuary Tulum

What Each Evidence Base Actually Shows

MDMA's trial design is narrower and more rigorous for PTSD specifically: a defined protocol, a placebo comparator, a single diagnostic target, and a multi-year phase 3 program. That rigor is real, and it is also why MDMA-assisted therapy remains confined to research and expanded-access frameworks rather than general clinical availability — the regulatory bar for a schedule I compound is high, and it has not yet been cleared.

Ayahuasca's evidence is broader but shallower on PTSD specifically: more naturalistic and observational studies, across a wider range of conditions including depression and substance use, with fewer randomized PTSD-specific trials. Neither pattern makes one substance objectively "better" for trauma — they represent different research investments and different regulatory paths, not a settled hierarchy of efficacy. See our ayahuasca for PTSD deep dive for more on the observational literature.

The Sanctuary Tulum Position

Sanctuary Tulum does not offer MDMA-assisted therapy. It is not an approved treatment, it is not legally available outside controlled research protocols, and honest clinical practice requires naming that plainly rather than implying access exists. What is offered is a plant-medicine protocol built around ayahuasca ceremonies and 5-MeO-DMT, paired with somatic bodywork, nervous-system regulation practices, and structured integration — all within a facility licensed by COFEPRIS, Mexico's federal health regulator. For guests whose clinical picture points toward MDMA-assisted therapy specifically, the appropriate step is enrollment in a licensed research or expanded-access program, not a substitute plant-medicine session marketed as equivalent.

Ayahuasca ceremony space at Sanctuary Tulum used for trauma-informed plant-medicine work

Who Each Approach Tends to Suit

Guests whose trauma is a single, clearly narratable event and whose primary goal is targeted reprocessing of that event in a reduced-fear state are the population MDMA-assisted therapy trials were designed around — which is precisely why access is currently limited to research settings rather than general availability. Guests whose trauma is developmental, preverbal, or somatically stored, or whose presentation includes overlapping depression, addiction, or existential distress, are more often the population described in the ayahuasca and broader classic-psychedelic literature.

This is a description of research populations and typical presentations, not a promise of outcome for any individual. A full intake — medical, psychiatric, and medication history — is required before any recommendation is made, and some guests are not appropriate candidates for either approach until other conditions are stabilized first. Learn more through our PTSD treatment program.

Practical and Safety Considerations

Both substances carry real medication-interaction risk. MDMA combined with an MAOI — including the MAOI present in ayahuasca — carries a documented serotonergic interaction risk and is treated as a hard contraindication rather than something addressed by simple spacing between sessions. Guests on SSRIs, SNRIs, or other serotonergic medications require a supervised medication review before either type of work is considered, since interrupting a stable antidepressant regimen carries its own withdrawal risk that must be managed by a physician rather than self-directed.

References

US-based readers evaluating travel logistics can also review our detailed guide on ayahuasca ceremonies near me for a NYC-focused breakdown of the legal landscape and licensed Mexico alternative.